202 related articles for article (PubMed ID: 22194030)
1. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients.
Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M
Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030
[TBL] [Abstract][Full Text] [Related]
2. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck.
Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654
[TBL] [Abstract][Full Text] [Related]
3. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer.
Zwicker F; Roeder F; Thieke C; Timke C; Münter MW; Huber PE; Debus J
Strahlenther Onkol; 2011 Jan; 187(1):32-8. PubMed ID: 21234529
[TBL] [Abstract][Full Text] [Related]
4. Treatment of locally advanced carcinomas of head and neck with intensity-modulated radiation therapy (IMRT) in combination with cetuximab and chemotherapy: the REACH protocol.
Habl G; Jensen AD; Potthoff K; Uhl M; Hof H; Hajda J; Simon C; Debus J; Krempien R; Münter MW
BMC Cancer; 2010 Nov; 10():651. PubMed ID: 21108850
[TBL] [Abstract][Full Text] [Related]
5. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of 6-month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck.
Matuschek C; Bölke E; Belka C; Ganswindt U; Henke M; Stegmaier P; Bamberg M; Welz S; Debus J; Gioules A; Voigt A; Volk G; Ohmann C; Wiegel T; Budach V; Stuschke M; Schipper J; Gerber PA; Budach W
Strahlenther Onkol; 2013 Aug; 189(8):625-31. PubMed ID: 23824104
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck.
Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F
Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383
[TBL] [Abstract][Full Text] [Related]
8. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck.
Balermpas P; Hambek M; Seitz O; Rödel C; Weiss C
Strahlenther Onkol; 2009 Dec; 185(12):775-81. PubMed ID: 20013086
[TBL] [Abstract][Full Text] [Related]
9. Impact of intensity-modulated and image-guided radiotherapy on elderly patients undergoing chemoradiation for locally advanced head and neck cancer.
Nguyen NP; Vock J; Chi A; Vinh-Hung V; Dutta S; Ewell L; Jang S; Betz M; Almeida F; Miller M; Davis R; Sroka T; Vo RP; Karlsson U; Vos P
Strahlenther Onkol; 2012 Aug; 188(8):677-83. PubMed ID: 22659942
[TBL] [Abstract][Full Text] [Related]
10. Hyperfractionated accelerated radiotherapy with concomitant integrated boost of 70-75 Gy in 5 weeks for advanced head and neck cancer. A phase I dose escalation study.
Cvek J; Kubes J; Skacelikova E; Otahal B; Kominek P; Halamka M; Feltl D
Strahlenther Onkol; 2012 Aug; 188(8):666-70. PubMed ID: 22648405
[TBL] [Abstract][Full Text] [Related]
11. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
[TBL] [Abstract][Full Text] [Related]
12. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
Heukelom J; Hamming O; Bartelink H; Hoebers F; Giralt J; Herlestam T; Verheij M; van den Brekel M; Vogel W; Slevin N; Deutsch E; Sonke JJ; Lambin P; Rasch C
BMC Cancer; 2013 Feb; 13():84. PubMed ID: 23433435
[TBL] [Abstract][Full Text] [Related]
13. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372
[TBL] [Abstract][Full Text] [Related]
14. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
15. Unilateral and bilateral neck SIB for head and neck cancer patients : Intensity-modulated proton therapy, tomotherapy, and RapidArc.
Stromberger C; Cozzi L; Budach V; Fogliata A; Ghadjar P; Wlodarczyk W; Jamil B; Raguse JD; Böttcher A; Marnitz S
Strahlenther Onkol; 2016 Apr; 192(4):232-9. PubMed ID: 26852243
[TBL] [Abstract][Full Text] [Related]
16. Phase I-II study of hypofractionated simultaneous integrated boost using volumetric modulated arc therapy for adjuvant radiation therapy in breast cancer patients: a report of feasibility and early toxicity results in the first 50 treatments.
Scorsetti M; Alongi F; Fogliata A; Pentimalli S; Navarria P; Lobefalo F; Garcia-Etienne C; Clivio A; Cozzi L; Mancosu P; Nicolini G; Vanetti E; Eboli M; Rossetti C; Rubino A; Sagona A; Arcangeli S; Gatzemeier W; Masci G; Torrisi R; Testori A; Alloisio M; Santoro A; Tinterri C
Radiat Oncol; 2012 Aug; 7():145. PubMed ID: 22929062
[TBL] [Abstract][Full Text] [Related]
17. Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas.
Levy A; Blanchard P; Bellefqih S; Brahimi N; Guigay J; Janot F; Temam S; Bourhis J; Deutsch E; Daly-Schveitzer N; Tao Y
Strahlenther Onkol; 2014 Sep; 190(9):823-31. PubMed ID: 24638267
[TBL] [Abstract][Full Text] [Related]
18. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.
Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK
Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418
[TBL] [Abstract][Full Text] [Related]
19. Concurrent hyperfractionated accelerated radiotherapy with 5-FU and once weekly cisplatin in locally advanced head and neck cancer. The 10-year results of a prospective phase II trial.
Budach V; Becker ET; Boehmer D; Badakhshi H; Jahn U; Wernecke KD; Stromberger C
Strahlenther Onkol; 2014 Mar; 190(3):250-5. PubMed ID: 24322993
[TBL] [Abstract][Full Text] [Related]
20. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
